ESRD, requiring dialysis, or severe hepatic impairment: not recommended. Do not substitute tabs and granules on a mg-per-mg basis. Severe uncontrolled hypertension: not recommended. Monitor blood ...
Low-cost competition in the US to Astellas’ Myrbetriq for urinary incontinence has arrived after a court recommended denying an injunction on the launch of generics. A US district court in ...
In 2014 Myrbetriq entered the extremely crowded, commoditized market of products with the intent to become leader in the Overactive Bladder (OAB) treatment category. Using TV, social media, apps and ...